Inverse nonlinear pharmacokinetics of total and protein unbound drug (oxaprozin): Clinical and pharmacokinetic implications

Journal of Clinical Pharmacology

Volumn 36, Issue 11, 1996, Pages 985-997

  Karim, Aziz ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; OXAPROZIN; PIROXICAM; SALICYLIC ACID;

ADULT; AGED; ANALGESIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTIPYRETIC ACTIVITY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG PROTEIN BINDING; FEMALE; HUMAN; HUMAN EXPERIMENT; INFLAMMATION; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL;

EID: 0030457168     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/009127009603601102     Document Type: Article

References (48)

1. Rowland M: Plasma protein binding and therapeutic drug monitoring. Ther Drug Mon 1980;2:29-37.
2. Svensson CK, Woodruff MN, Baxter JG, Lalka D: Free drug concentration monitoring in clinical practice: rationale and current status. Clin Pharmacokinet 1986;11:450-469.
3. MacKichan JJ: Influence of protein binding and use of unbound (free) drug concentrations. In, Evans WE, Schentag JJ, Jusko, WJ (eds.): Applied Pharmacokinetics: Principles of Therapeutic Drug Monitoring. Third edition. Vancouver, WA: Applied Therapeutics, Inc., 1992;37-39.
4. du Souich P, Verges J, Erill S: Plasma protein binding and pharmacological response. Clin Pharmacokinet 1993;24:435-440.
5. Wanwimolruk S, Birkett DJ, Brooks PM: Protein binding of some nonsteroidal antiinflammatory drugs in rheumatoid arthritis. Clin Pharmacokinet 1982;7:85-92.
6. Verbeeck RK, Blackburn JL, Loewen GR: Clinical pharmacokinetics of nonsteroidal antiinflammatory drugs. Clin Pharmacokinet 1983;8:297-331.
7. Wallace SM, Verbeeck RK: Plasma protein binding of drugs in elderly. Clin Pharmacokinet 1987;12:41-72.
8. Lin JH, Cocchetto DM, Duggan DE: Protein binding as a primary determinant of the clinical pharmacokinetic properties of nonsteroidal antiinflammatory drugs. Clin Pharmacokinet 1987;12:402-432.
9. Verbeeck RK: Pathophysiologic factors affecting the pharmacokinetics of nonsteroidal antiinflammatory drugs. J Rheumatol 1988;15(Suppl 17):44-57.
10. Runkel R, Forchielli E, Sevelius H, Chaplin M, Segre E: Non-linear plasma level response to high doses of naproxen. Clin Pharmacol Ther 1973;15:261-266.
11. Runkel R, Chaplin MD, Sevelius H, Ortega E, Segre E: Pharmacokinetics of naproxen overdoses. Clin Pharmacol Ther 1976;20:269-277.
12. Upton RA, Williams RL, Kelly J, Jones RM: Naproxen pharmacokinetics in the elderly. Br J Clin Pharmacol 1984;18:202-214.
13. Furst DE, Tozer TN, Melmon KL: Salicylate clearance, the resultant of protein binding and metabolism. Clin Pharmacol Ther 1979;26:380-389.
14. Needs CJ, Brooks PM: Clinical pharmacokinetics of the salicylates. Clin Pharmacokinet 1985;10:164-177.
15. Rowland M, Tozer TN: Clinical Pharmacokinetics: Concepts and Applications. Third edition. Philadelphia: Lea & Febiger, 1995;394-418.
16. Verbeeck R, Tjandramaga TB, Mullie A, Verbesselt R, Verberckmoes R, De Schepper PJ: Biotransformation of diflunisal and renal excretion of its glucuronides in renal insufficiency. Br J Clin Pharmacol 1979;7:273-282.
17. Verbeeck RK, Boel A, Buntinx A, De Schepper PJ: Plasma protein binding and interaction studies with diflunisal, a new salicylate analgesic. Biochem Pharmacol 1980;29:571-576.
18. Levy G: Effect of plasma protein binding of drugs on duration and intensity of pharmacological activity. J Pharm Sci 1976;65:1264-1265.
19. McNamara PJ, Levy G, Gibaldi M: Effect of plasma protein and tissue binding on the time course of drug concentration in plasma. J Pharmacokinet Biopharm 1979;7:195-206.
20. Oie S, Guentert TW, Tozer TN: Effect of saturable binding on the pharmacokmetics of drugs: a simulation. J Pharm Pharmacol 1980;32:471-477.
21. Tozer TN: Concepts basic to pharmacokinetics. Pharmacol Ther 1981;12:109-131.
22. Wilkinson GR: Plasma and tissue binding considerations in drug disposition. Drug Metab Rev 1983;14:427-465.
23. Ludden TM: Nonlinear pharmacokinetics: clinical implications. Clin Pharmacokinet 1991;20:429-446.
24. Rosenthale ME, Begany AJ, Dervinis A, Malis JL, Shriver DA, Datko LG, Gluckman MI: Antiinflammatory properties of 4,5-diphenyl-2-oxazolepropionic acid (oxaprozin). Agents Actions 1974;4:151-159.
25. Janssen FW, Jusko WJ, Chiang ST, Kirkman SK, Southgate PJ, Coleman AJ, Ruelius HW: Metabolism and kinetics of oxaprozin in normal subjects. Clin Pharmacol Ther 1980;27:352-362.
26. Homon CA, Fluck ER, Janssen FW, Ruelius HR: Protein binding and clearance of oxaprozin, a highly bound antiinflammatory agent. Agent Actions 1982;12:211-215.
27. Chiang ST, Morrison G, Knowles JA, Ruelius HW, Walker BR: Oxaprozin disposition in renal disease. Clin Pharmacol Ther 1982;31:509-515.
28. Chiang ST, Lasseter KC, Fluck ER, Janssen FW, Leelavathi D, Hubsher JA: Oxaprozin dose proportionality. J Clin Pharmacol 1984;24:515-522.
29. McHugh SL, Kirkman SK, Knowles JA: Macro- and micro-methods for high-performance liquid chromatographic analysis of oxaprozin in plasma. J Pharm Sci 1980;69:794-796.
30. Greenblatt DJ, Matlis R, Scavone JM, Blyden GT, Harmatz JS, Shader RI: Oxaprozin pharmacokinetics in the elderly. Br J Clin Pharmacol 1985;19:373-378.
31. Todd PA, Brogden RN: Oxaprozin: a preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy. Drugs 1986;32:291-312.
32. Greenblatt DJ, Scavone JM: Pharmacokinetics of oxaprozin and other nonsteroidal antiinflammatory agents. Semin Arthritis Rheum 1986;15:18-26.
33. Divine C, Lemeur A, Fredj G, Durand JL, Thuillier A: Pharmacokinetic study of oxaprozine after single dose and chronic regimen in healthy volunteers: influence of sex and protein binding. J Pharm Clin 1986;5:413-423.
34. Suwa T, Urano H, Tsuji A: Pharmacokinetics of oxaprozin after multiple doses. J Pharm Soc Jpn 1987;107:440-448.
35. Audet PR, Knowles JA, Troy SM, Walker BR, Morrison G: Effect of chronic renal failure on oxaprozin multiple-dose pharmacokinetics. Clin Pharmacol Ther 1988;44:303-309.
36. Miller LG: Oxaprozin: a once-daily nonsteroidal antiinflammatory drug. Clin Pharm 1992;11:591-603,
37. Forrest A, Collins DA, Longstreth J: Population plasma pharmacokinetics of unbound and total oxaprozin in normal volunteers (abstract). Pharmacotherapy 1993;13:291.
38. Verbeeck RK, Wallace SM: Nonsteroidal antiinflammatory drugs: restrictive or nonrestrictive hepatic clearance? Arzneimittelforschung 1994;44:683-685.
39. Hejmanowski LG, Keem RF, Adams MH, Longstreth J, Wilton JH: Determination of free oxaprozin plasma concentrations by ultrafiltration (abstract). Pharm Res 1993;10:S46.
40. Brogden RN, Heel RC, Speight TM, Avery GS: Piroxicam: a review of its pharmacological properties and therapeutic efficacy. Drugs 1981;22:165-187.
41. Adams MH, Forrest A, Wilton JH, McMahon FG, Longstreth JA: Effect of age on the steady-state pharmacokinetics of oxaprozin and piroxicam (abstract). Pharm Res 1994;11:S101.
42. Jahnchen E, Levy G: Inhibition of phenylbutazone elimination by its metabolite oxyphenylbutazone. Proc Soc Exp Biol Med 1972;141:963-965.
43. Ashley JJ, Levy G: Kinetics of diphenylhydantoin elimination in rats. J Pharmacokinet Biopharm 1973;1:99-102.
44. Lin JH, Hooke KF, Yeh KC, Duggan DE: Dose dependent pharmacokinetics of diflunisal in rats: dual effects of protein binding and metabolism. J Pharmacol Exp Ther 1985;235:402-406.
45. Spahn-Langguth H, Benet LZ: Acyl glucuronides revisited: is the glucuronidation process a toxification as well as a detoxification mechanism? Drug Metab Rev 1992;24:5-48.
46. Boxenbaum H, Battle M: Effective half-life in clinical pharmacology. J Clin Pharmacol 1995;35:763-766.
47. Graham GG: Pharmacokinetics and metabolism of nonsteroidal antiinflammatory drugs. Med J Aust 1987;147:597-602.
48. Brooks PM, Day RO: Nonsteroidal antiinflammatory drugs: differences and similarities. New Engl J Med 1991;324:1716-1725.